

# Comparison of Epidemiological and Antibiotic Susceptibility Pattern of Metallo-Beta-Lactamase-Positive and Metallo-Beta-Lactamase-Negative Strains of *Pseudomonas Aeruginosa*

Shikha Ranjan, Banashankari GS, PR Sreenivasa Babu

Department of Microbiology, MS Ramaiah Medical College, Bangalore, Karnataka, India

**Address for correspondence:** Dr. Shikha Ranjan, E-mail: shiksthakur@gmail.com

## ABSTRACT

**Background:** The infections caused by metallo-beta-lactamases (MBLs) producing *Pseudomonas aeruginosa* are associated with higher rates of mortality, morbidity, and overall healthcare costs compared to non-MBL *P. aeruginosa* infections.

**Purpose:** To compare the epidemiologic factors and antibiograms of MBL-positive and MBL-negative *P. aeruginosa* isolates in a tertiary care hospital.

**Methods:** In an observational study, from January 2011 to December 2012, all non-duplicate *P. aeruginosa* isolates were subjected to an antimicrobial sensitivity test against 10 antibiotics of five different classes. All *P. aeruginosa* strains showing resistance to at least one of the carbapenems were subjected to the MBL-E test. Epidemiological features and antibiograms of MBL-positive and MBL-negative strains were compared and statistically analyzed.

**Results:** Out of 350 isolates (total sample = 5330) of *P. aeruginosa*, MBL was detected in 58 isolates by the E-test, resulting in a prevalence of 16.57%. Resistance to most of the antibiotics was significantly higher in the MBL-positive strains with 100% resistance to ciprofloxacin, tobramycin, and meropenem, followed by imipenem (93.10%) and gentamicin (89.66%). The prevalence of multidrug-resistant and pandrug-resistant strains was significantly higher among the MBL group as compared to that in the non-MBL group ((55.17 vs. 7.88% ( $P < 0.0001$ ) and 8.62 vs. 0.68% ( $P = 0.0006$ )), respectively.

**Conclusions:** MBL-positive *P. aeruginosa* strains showed very high resistance to various antibiotics, as compared to the non-MBL strains. Increasing prevalence of MBL-producing isolates in hospital settings makes it important to perform routine detection of MBL-positive *P. aeruginosa* strains by *in vitro* testing before antibiotic use, for the purposes of infection prevention, and control, and for minimizing the adverse outcomes of infections with MBL-producing strains.

**Key words:** Antibiogram, epidemiological factors, metallo-beta-lactamases, non-metallo-beta-lactamases, *P. aeruginosa*

## INTRODUCTION

Treatment of infectious diseases is becoming more challenging with each passing year. This is especially true for infections caused by the opportunistic pathogen *Pseudomonas aeruginosa* (*P. aeruginosa*), due to

its ability to rapidly develop resistance to multiple classes of antibiotics.<sup>[1]</sup> *P. aeruginosa* is well-known for its persistence in the hospital environment, and hence, multidrug resistance mechanisms are often seen in such hospital isolates.<sup>[2]</sup> Carbapenems are the antibiotics of choice for severe *Pseudomonas* infections, however, in recent years resistance to this novel antibiotic is increasing worldwide.<sup>[3]</sup> The most common mechanism for carbapenem resistance is production of metallo-beta-lactamases (MBLs), which are broad-spectrum enzymes that hydrolyze most beta-lactam antibiotics, and are not inhibited by conventional beta-lactamase inhibitors like clavulanic acid or sulbactam.<sup>[2]</sup> Since the first reporting of

Access this article online	
Quick Response Code:	Website: www.jlponline.org
	DOI: 10.4103/0974-2727.141509

MBL-producing *P. aeruginosa* in Japan, in 1991, infection with MBL-producing organisms has become a major problem in various parts of the world.<sup>[4]</sup> The infections caused by MBL-producing *P. aeruginosa* are associated with higher rates of mortality, morbidity, need for surgical intervention, length of hospital stay and chronic care, and overall healthcare costs compared to non-MBL-producing *P. aeruginosa* infections.<sup>[1,2,4,5]</sup>

The evolution, maintenance, and dissemination of MBL genes in *P. aeruginosa* populations in larger geographic healthcare regions is a dynamic process that requires ongoing study.<sup>[6]</sup> Although the import of resistance mechanisms on mobile genetic elements is always a concern, the most difficult challenge faced with *P. aeruginosa* is its ability to rapidly develop resistance during the course of treating an infection.<sup>[1]</sup> The lack of antibiotic policy in a hospital and sale of antibiotics over the counter, without prescription, leads to indiscriminate and injudicious use of antibiotics, further increasing the burden of antimicrobial resistant organisms. Therefore, there is a need to have a strong antibiotic policy, which is revised from time-to-time, with a stringent check over the sale of antibiotics, and incorporation of an antibiotic stewardship program. Hence, this study was conducted to detect the presence of MBLs in *P. aeruginosa* isolates obtained from the clinical sample, from a tertiary care hospital in South India, and to compare the antibiograms of MBL-producing and non-MBL-producing *P. aeruginosa* isolates, to guide clinicians in prescribing proper antibiotics and controlling hospital infection.

## MATERIALS AND METHODS

This prospective study was conducted from January, 2011 to December, 2012, in the Department of Microbiology, MS Ramaiah Medical College, Bangalore, India. The Institutional Review Board approval was obtained for this study (study registration No.- 01\_M010\_16928) and all the principles of the Declaration of Helsinki were followed.

Routine clinical specimens from all medical and surgical departments sent to the Department of Microbiology for culture and sensitivity were included. All specimens including a pus swab, endotracheal lavages, blood, sputum, catheter tips, and urine were processed according to the standard microbiological procedures. Isolates were identified as *P. aeruginosa* by the bluish-green pigmentation, growth at 42°C, and a positive arginine dihydrolysis test. All the non-duplicate *P. aeruginosa* isolates recovered during this period were subjected to antimicrobial sensitivity

testing by employing the Kirby Bauer disk diffusion technique as per the Clinical and Laboratory Standards Institute (CLSI) guidelines.<sup>[7]</sup> The antibiotic susceptibility of all *P. aeruginosa* isolates was determined against the following antibiotics: Ceftazidime (30 µg), cefepime (30 µg), gentamicin (10 µg), amikacin (30 µg), tobramycin (10 µg), netilmicin (30 µg), ciprofloxacin (5 µg), aztreonam (30 µg), meropenem (10 µg), and imipenem (10 µg). All the disks were procured commercially from the same source (Hi-media laboratories limited, India). The diameter of the zone of inhibition was measured and interpreted according to the CLSI guidelines. The different classes of antibiotics, evaluated in this study, were defined as cephalosporins, aminoglycosides, fluoroquinolones, monobactams, and carbapenems. Isolates resistant to all the antimicrobials of at least three classes used in this study were defined as multidrug-resistant (MDR) strains. Isolates resistant to all the antimicrobials of all the classes used in this study were defined as pandrug-resistant (PDR) isolates. All *P. aeruginosa* strains that were found to be resistant to at least one of the carbapenems (imipenem or/and meropenem) using the disk diffusion test were screened for MBL activity. MBL-E test (Imipenem/ethylene diamine tetra acetic acid E- test: IMP/EDTA Epsilon-meter-test) (Hi-media laboratories limited, India) was applied to all positively screened isolates, to confirm the presence of the MBL phenotype. The E-test was performed following the CLSI recommendations and manufacturer's instructions. The MIC ratio of IMP/IMP-EDTA of  $\geq 8$  was interpreted as being indicative of MBL production.

On the basis of the result of the E-test, *P. aeruginosa* isolates were divided into two groups MBL-producing and non-MBL-producing strains, and retrospectively their epidemiological features and antibiograms were compared. All findings were entered in an MS excel data sheet and on completion of the study data were statistically analyzed. The data was expressed as mean  $\pm$  SD and percentages.

## RESULTS

During the study period, a total of 350 isolates of *P. aeruginosa* was collected. The mean age of all the patients, from whom isolates were collected, was  $43.68 \pm 19.41$  years. The male to female ratio of the study sample was 1.85 ( $n = 227:123$ ). Out of 350 isolates of *P. aeruginosa*, MBL was detected in 58 isolates by E-test, while the remaining 292 isolates were MBL-negative. Thus, the prevalence of MBL-producing strains among the clinical isolates of *P. aeruginosa* collected in our study was 16.57% (95% CI: 12.67–20.47). There was no statistical difference between the mean age of

the patients infected with MBL-positive *P. aeruginosa* isolates and of those with MBL-negative *P. aeruginosa* isolates ( $43.97 \pm 18.02$  and  $43.62 \pm 19.70$  years, respectively,  $P = 0.9026$ ). Table 1 shows the demographic comparison of patients infected with MBL-producing and non-MBL-producing *P. aeruginosa* isolates. Out of 58 MBL-positive *P. aeruginosa*, 42 isolates (72.41%) were recovered from male patients and 16 isolates (27.59%) from female patients. Among 292 non-MBL-producing *P. aeruginosa* isolates, 185 isolates (63.36%) were recovered from males and 107 isolates (36.64%) from females. The age-group distribution pattern for MBL-positive and MBL-negative *P. aeruginosa* isolates were statistically similar ( $P = 0.6890$ ). For both the groups, the isolates were collected most commonly from the 41-60-year age group (41.38 and 38.01%, respectively) followed by the 21-40-year age group (36.21 and 26.37%, respectively). The sample-wise distribution of MBL-positive and MBL-negative *P. aeruginosa* isolates has been summarized in Table 2. For both MBL-producing and non-MBL-producing *P. aeruginosa*, the most common sample source was pus (48.28 and 51.03%, respectively) followed by urine (13.79 and 20.21%, respectively).

Table 3 shows and compares the result of an antibiogram, for routinely tested antimicrobial agents of MBL-producing and non-MBL-producing *P. aeruginosa* isolates. Resistance to all the antibiotics used in the study, except ceftazidime and netilmicin, was significantly more common in the MBL-producing strains, compared to that in the non-MBL-producing strains. The MBL-producing isolates showed 100% resistance to ciprofloxacin, tobramycin, and meropenem, followed by imipenem (93.10%) and gentamicin (89.66%), while resistance to these antibiotics by the non-MBL-producing isolates was 39.73, 52.74, 6.8%, 8.22, and 32.53%, respectively. The prevalence of multidrug-resistant and pandrug-resistant isolates was significantly higher among the MBL group as compared to that in the non-MBL group (55.17 vs. 7.88% ( $P < 0.0001$ ) and (8.62% vs. 0.68% ( $P = 0.0006$ ), respectively [Table 4].

## DISCUSSION

The occurrence of MBL-producing *P. aeruginosa* isolates in a hospital setting poses a therapeutic problem as well as a serious concern for infection control management, due to the rapid spread of these multidrug-resistant isolates.<sup>[4]</sup> In our present study, the prevalence of MBL-producing isolates was 16.57%, while in a previous study from our hospital (2002), the MBL-production in *P. aeruginosa* was recorded as 12%.<sup>[8]</sup> Thus, the prevalence of MBL-producing *P. aeruginosa* strains

**Table 1: Comparison of the demographic details of MBL-positive and MBL-negative *P. aeruginosa* isolates**

Characteristics	MBL-positive	MBL-negative	Statistical analysis
Mean age (years)	43.97±18.02	43.62±19.70	$P=0.9026^*$
Groups	Number of subjects (n (%))		
Sex distribution			
Male	42 (72.41)	185 (63.36)	$P=0.2423^{**}$
Female	16 (27.59)	107 (36.64)	
Age-group distribution (years)			
1-20	6 (10.34)	46 (15.75)	$P=0.6890^{\#}$
21-40	21 (36.21)	77 (26.37)	
41-60	24 (41.38)	111 (38.01)	
61-80	5 (8.62)	51 (17.47)	
>80	2 (3.45)	7 (2.40)	

\*Unpaired t test with Welch correction, two-tailed P value, \*\* Chi-squared ( $\chi^2$ ) test with Yate's correction, two-tailed P value,  $\#$ Chi-squared ( $\chi^2$ ) test for trend with Yate's correction, two-tailed P value

**Table 2: Comparison of sample-wise distribution of MBL-positive and MBL-negative *P. aeruginosa* isolates**

Types of sample	Number of isolates (percentage)	
	MBL-Positive (58)	MBL-Negative (292)
Pus	28 (48.28)	149 (51.03)
Urine	8 (13.79)	59 (20.21)
ET Secretion	7 (12.07)	25 (8.56)
Tissue	6 (10.34)	18 (6.16)
Sputum	3 (5.17)	17 (5.82)
Blood	2 (3.45)	13 (4.45)
Miscellaneous	4 (6.90)	11 (3.77)

MBL: Metallo-beta-lactamases, ET: Endotracheal tube

**Table 3: Comparison of antibiogram of MBL-positive and MBL-negative *P. aeruginosa* isolates**

Antibiotics	Number of resistant isolates (percentage)		Statistical analysis*
	MBL-Positive (58)	MBL-Negative (292)	
Amikacin	24 (41.38)	49 (16.78)	$P<0.0001$
Aztreonam	31 (53.45)	91 (31.16)	$P=0.0019$
Cefepime	24 (41.38)	39 (13.36)	$P<0.0001$
Ceftazidime	17 (29.31)	79 (27.05)	$P=0.8489$
Ciprofloxacin	58 (100)	116 (39.73)	$P<0.0001$
Gentamicin	52 (89.66)	95 (32.53)	$P<0.0001$
Imipenem	54 (93.10)	24 (8.22)	$P<0.0001$
Meropenem	58 (100)	20 (6.85)	$P<0.0001$
Netilmicin	32 (55.17)	125 (42.81)	$P=0.1130$
Tobramycin	58 (100)	154 (52.74)	$P<0.0001$

\*Chi-squared test with Yate's correction, two-tailed P value, MBL: Metallo-beta-lactamases

**Table 4: Prevalence of MDR and PDR isolates among MBL-positive and MBL-negative *P. aeruginosa***

Groups	Number of isolates (%)		Statistical analysis*
	MBL positive [58]	MBL negative [292]	
MDR isolates	32 (55.17%)	23 (7.88%)	$P<0.0001$
PDR isolates	5 (8.62%)	2 (0.68%)	$P=0.0006$

\* Chi-squared test with Yate's correction, two-tailed P value, MDR: Multidrug-resistant, PDR: Pandrug-resistant, MBL: Metallo-beta-lactamases

in our hospital seemed to have increased by about 5% in a decade. However, in a similar study, Vitkauskienė *et al.* reported the prevalence of MBL-producing *P. aeruginosa* as 15.8%, in 2003, which increased to 61.9%, in 2008, resulting in a 46% rise in only a five-year period.<sup>[9]</sup> These results clearly demonstrate the increasing burden of MBL strains in the same hospital setup, although the rate of increment varies widely. Interestingly, in our setup the increase in the MBL-positive strain from 2002 to 2012 has not been very drastic (12 to 16.57%) in contrast to the study by Vitkauskienė *et al.*<sup>[9]</sup> In India, the incidence of MBL production in *P. aeruginosa* has been reported to be 10-30% from various clinical specimens across the country.<sup>[10]</sup> A similar prevalence rate of MBL-producing strains of *P. aeruginosa* has been observed in studies conducted by Hemalatha V *et al.*<sup>[11]</sup> in Chennai, India (14%), Saderi H *et al.*<sup>[12]</sup> in Brazil (19.7%) and Mihani *et al.*<sup>[13]</sup> in Iran (19.51%).

The present study has tried to compare the demographic factors associated with the development of infections caused by MBL-producing and non-MBL-producing isolates of *P. aeruginosa* in the general population. We observed no significant difference in the age-distribution pattern for both the groups with infection being most prevalent in the 40-60-year age group followed by 20-40-year age group. Similar observations have been reported by Anupurba S *et al.*<sup>[14]</sup> We observed a significantly higher rate of infection caused by both MBL and non-MBL strains, although there was no difference in the sex-distribution pattern between the two groups. This observation was also in accordance with the results of Anupurba S *et al.* suggesting that males are more predisposed to acquire *P. aeruginosa* infection.<sup>[14]</sup> Also, no difference was observed between the two groups in terms of most frequent sample sources.

Our study has illustrated that the MBL-producing strains are an important cause of resistance to commonly used antimicrobial agents. MBL-producing isolates showed the highest resistance to the fluoroquinolone (ciprofloxacin 100%), aminoglycosides (tobramycin 100% and gentamicin 89.66%), and carbapenems (meropenem 100% and imipenem 93.10%). Several studies have also highlighted greater resistance exhibited by MBL-positive strains toward almost all classes of antimicrobials, as compared to MBL-negative strains. Viskauskienė *et al.* have also reported that MBL-producing *P. aeruginosa* strains are significantly more commonly resistant to ciprofloxacin, gentamicin, ceftazidime, cefepime, aztreonam, and piperacillin, as compared to MBL-negative strains.<sup>[8]</sup> Similar findings were reported by Hemlatha *et al.*,<sup>[11]</sup> Navneeth *et al.*,<sup>[8]</sup> and Varaiya *et al.*<sup>[15]</sup> Thus, MBL strains are developing resistance to not only carbapenems, but are also resistant to other commonly

used drugs, thus rendering them ineffective. This suggests a possible existence of co-resistance to quinolones, aminoglycosides, and other classes of antibiotics on the gene responsible for MBL production. Interestingly in our study, resistance to ceftazidime was pretty low (29.3%) as compared to the finding of Arunagiri *et al.*, who has reported 100% resistance to ceftazidime.<sup>[10]</sup> This may be because of a lower pressure of selecting ceftazidime in treating pseudomonal infection and increasing the trend of using carbapenems, in our hospital.

The prevalence of multidrug-resistant isolates (resistant to three or more classes of antibiotics) was significantly higher in the MBL group (55.17%) as compared to the non-MBL group (7.88%) ( $P < 0.0001$ ). A similar result was found in the study conducted by Laupland *et al.*, in which 89% of the MBL-producing strains were resistant to three classes of antibiotics, in addition to imipenem, whereas, resistance to antibiotics was uncommon (7%) in the non-MBL-producing isolates ( $P < 0.0001$ ).<sup>[6]</sup> In our study, 8.62% of the MBL-producing strains were found to be resistant to all the classes of antimicrobials used in the study, whereas, only 0.68% of the non-MBL-producing strains were pandrug-resistant ( $P = 0.0006$ ). Today the growing population of pan-resistant bacteria, including MBL-producing *P. aeruginosa*, threatens to move us into what some consider the 'post-antibiotic era' of infectious disease.<sup>[1]</sup> The significantly higher prevalence of multidrug- and pandrug-resistance among MBL-producing strains, as compared to that in non-MBL-producing strains supports the notion that clinical microbiological laboratories must be able to distinguish MBL-producing strains from those with other mechanisms responsible for carbapenem resistance. The identification of MBL production in *P. aeruginosa* isolates also has clinical implications, because such isolates are more likely to cause invasive disease and are associated with a higher hospital case-fatality rate, compared with other imipenem-resistant isolates.<sup>[6,16]</sup>

To conclude, the prevalence of MBL-producing *P. aeruginosa* isolates in hospital settings are increasing day by day, leading to more treatment failure with commonly used antibiotics. Although there is no difference in the epidemiological factors associated with MBL-producing and non-MBL-producing *P. aeruginosa*, they differ greatly in their susceptibility to various antibiotics. The routine detection and molecular characterization of MBL-producing *P. aeruginosa* strains by *in vitro* testing, before antibiotic use, is important for the purposes of infection prevention and control, and potentially for defining the risk for development of severe disease, and for minimizing the adverse outcomes associated with MBL-producing strains.



## REFERENCES

1. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 2009;22:582-610.
2. Kali A, Srirangaraj S, Kumar S, Divya HA, Kalyani A, Umadevi S. Detection of metallo-beta-lactamase producing *Pseudomonas aeruginosa* in intensive care units. *Australas Med J* 2013;6:686-93.
3. Hammami S, Boutiba-Ben Boubaker I, Ghazzi R, Saidani M, Amine S, Ben Redjeb S. Nosocomial outbreak of imipenem-resistant *Pseudomonas aeruginosa* producing VIM-2 metallo-beta-lactamase in a kidney transplantation unit. *Diagn Pathol* 2011;6:106.
4. Kaleem F, Usman J, Hassan A, Khan A. Frequency and susceptibility pattern of metallo-beta-lactamase producers in a hospital in Pakistan. *J Infect Dev Ctries* 2010;4:810-3.
5. Zavascki AP, Barth AL, Goncalves AL, Moro AL, Fernandes JF, Martins AF, *et al.* The influence of metallo-beta-lactamase production on mortality in nosocomial *Pseudomonas aeruginosa* infections. *J Antimicrob Chemother* 2006;58:387-92.
6. Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, *et al.* Population-based epidemiological study of infections caused by carbapenem-resistant *Pseudomonas aeruginosa* in the Calgary Health Region: Importance of metallo-beta-lactamase (MBL)-producing strains. *J Infect Dis* 2005;192:1606-12.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disks Susceptibility Tests; Approved Standard. 10<sup>th</sup> ed. CLSI document M02-A10. Wayne, PA: CLSI; 2009.
8. Navaneeth BV, Sridaran D, Sahay D, Belwadi MR. A preliminary study on metallo-beta-lactamase producing *Pseudomonas aeruginosa* in hospitalized patients. *Indian J Med Res* 2002;116:264-7.
9. Vitkauskienė A, Skrodenienė E, Dambrauskienė A, Bakšytė G, Macas A, Sakalauskas R. Characteristics of carbapenem-resistant *Pseudomonas aeruginosa* strains in patients with ventilator-associated pneumonia in intensive care units. *Medicina (Kaunas)* 2011;47:652-6.
10. Arunagiri K, Sekar B, Sangeetha G, John J. Detection and characterization of metallo-beta-lactamases in *Pseudomonas aeruginosa* by phenotypic and molecular methods from clinical samples in a tertiary care hospital. *West Indian Med J* 2012;61:778-83.
11. Hemalatha V, Sekar U, Kamat V. Detection of metallo beta-lactamase producing *Pseudomonas aeruginosa* in hospitalized patients. *Indian J Med Res* 2005;122:148-52.
12. Saderi H, Karimi Z, Owlia P, Bahar MA, Rad SM. Phenotypic detection of metallo-beta-lactamase producing *pseudomonas aeruginosa* strains isolated from burned patients. *Iran J Pathol* 2008;3:20-4.
13. Mihani F, Khosravi A. Isolation of *P. aeruginosa* strains producing metallo beta lactamases from infections in burned patients and identification of blaIMP and blaVIM genes by PCR. *Iran J Med Microbiol* 2007;1:23-31.
14. Anupurba S, Bhattacharjee A, Garg A, Sen MR. Antimicrobial susceptibility of *Pseudomonas aeruginosa* isolated from wound infections. *Indian J Dermatol* 2006;51:286-8.
15. Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo beta lactamase producing *Pseudomonas aeruginosa* in ICU patients. *Indian J Med Res* 2008;127:398-402.
16. Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, Aoki S, *et al.* Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing *pseudomonas aeruginosa*. *Clin Infect Dis* 2003;37:26-32.

**How to cite this article:** Ranjan S, Banashankari GS, Sreenivasa Babu PR. Comparison of epidemiological and antibiotic susceptibility pattern of metallo-beta-lactamase-positive and metallo-beta-lactamase-negative strains of *pseudomonas aeruginosa*. *J Lab Physicians* 2014;6:109-13.

**Source of Support:** Nil. **Conflict of Interest:** None declared.